The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
It signals Cordis' renewed investment in innovation
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Subscribe To Our Newsletter & Stay Updated
